首页> 外文期刊>BMJ Open >Can the painDETECT Questionnaire score and MRI help predict treatment outcome in rheumatoid arthritis: protocol for the Frederiksberg hospital's Rheumatoid Arthritis, pain assessment and Medical Evaluation (FRAME-cohort) study
【24h】

Can the painDETECT Questionnaire score and MRI help predict treatment outcome in rheumatoid arthritis: protocol for the Frederiksberg hospital's Rheumatoid Arthritis, pain assessment and Medical Evaluation (FRAME-cohort) study

机译:painDETECT问卷评分和MRI能否帮助预测类风湿关节炎的治疗结果:腓特烈堡医院类风湿关节炎的方案,疼痛评估和医学评估(FRAME-队列)研究

获取原文
           

摘要

Introduction Pain in rheumatoid arthritis (RA) is traditionally considered to be of inflammatory origin. Despite better control of inflammation, some patients still report pain as a significant concern, even when being in clinical remission. This suggests that RA may prompt central sensitisation—one aspect of chronic pain. In contrast, other patients report good treatment response, although imaging shows signs of inflammation, which could indicate a possible enhancement of descending pain inhibitory mechanisms. When assessing disease activity in patients with central sensitisation, the commonly used disease activity scores (eg, DAS28-CRP (C reactive protein)) will yield constant high total scores due to high tender joint count and global health assessments, whereas MRI provides an isolated estimate of inflammation. The objective of this study is, in patients with RA initiating anti-inflammatory treatment, to explore the prognostic value of a screening questionnaire for central sensitisation, hand inflammation assessed by conventional MRI, and the interaction between them regarding treatment outcome evaluated by clinical status (DAS28-CRP). For the purpose of further exploratory analyses, dynamic contrast-enhanced MRI (DCE-MRI) is performed. Method and analysis The painDETECT Questionnaire (PDQ), originally developed to screen for a neuropathic pain component, is applied to indicate the presence of central sensitisation. Adults diagnosed with RA are included when either (A) initiating disease-modifying antirheumatic drug treatment, or (B) initiating or switching to biological therapy. We anticipate that 100 patients will be enrolled, tested and reassessed after 4?months of treatment. Data collection includes Clinical data, conventional MRI, DCE-MRI, blood samples and patient-reported outcomes. Ethics and dissemination This study aims at supporting rheumatologists to define strategies to reach optimal treatment outcomes in patients with RA based on chronic pain prognostics. The study has been approved by The Capital region of Denmark's Ethics Committee; identification number H-3-2013-049. The results will be published in international peer-reviewed journals.
机译:简介传统上,类风湿关节炎(RA)的疼痛被认为是发炎的。尽管可以更好地控制炎症,但即使在临床缓解的情况下,一些患者仍然认为疼痛是一个重要问题。这表明RA可能会促使中枢致敏,这是慢性疼痛的一个方面。相反,其他患者报告了良好的治疗反应,尽管影像学显示炎症迹象,这可能表明疼痛抑制机制可能增强。在评估中枢敏化患者的疾病活动时,由于高的关节总数和整体健康评估,常用的疾病活动评分(例如DAS28-CRP(C反应蛋白))将产生恒定的高总评分,而MRI提供了隔离的估计炎症。这项研究的目的是,对于RA发起抗炎治疗的患者,探讨针对中枢敏化,通过常规MRI评估手部炎症以及通过临床状态评估治疗结果之间相互作用的筛查问卷的预后价值( DAS28-CRP)。为了进一步的探索性分析,进行了动态对比增强MRI(DCE-MRI)。方法和分析最初开发用于筛选神经性疼痛成分的painDETECT问卷(PDQ)用于指示中枢敏化的存在。当(A)开始改变疾病的抗风湿药物治疗,或(B)开始或转向生物治疗时,包括被诊断为RA的成人。我们预计在治疗4个月后,将有100名患者入组,测试并重新评估。数据收集包括临床数据,常规MRI,DCE-MRI,血液样本和患者报告的结局。伦理与传播本研究旨在支持风湿病学家根据慢性疼痛的预后,确定可在RA患者中达到最佳治疗效果的策略。该研究已获得丹麦伦理委员会首都地区的批准;识别号H-3-2013-049。结果将在国际同行评审期刊上发表。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号